Issue: Exclusive Online Content, Posted Date: 1/22/2015
Colorectal Cancer Treatment Market Value to Hit $9.4 Billion
The value of the Colorectal Cancer (CRC) therapeutics
market will increase moderately, from $8.3 billion in 2013 to $9.4 billion by
2020, representing a Compound Annual Growth Rate (CAGR) of 1.8%, according to
business intelligence provider GBI Research.
The company’s latest report, Colorectal Cancer Therapeutics in Major Developed Markets
to 2020 - Increased Uptake of High Priced Drugs to Offset the Impact of Generics,
states that this growth, which will occur across eight major developed
countries, namely the US, UK, France, Germany, Spain, Italy, Japan and Canada,
will be limited by the patent expirations of Avastin and Erbitux during the
forecast period, which will prompt the uptake of lower-priced biosimilar
versions of these drugs.
However, Saurabh Sharma, Senior Analyst for
GBI Research, says that despite its patent expiration, Avastin is expected to
retain its market-leading position in the global CRC space through to 2020.
Sharma explains “Avastin is heavily
prescribed in both first- and second-line settings, regardless of the patient’s
K-Ras status. Its dominance is consistent across both the metastatic K-Ras
wild-type and mutation-positive settings, despite the availability of epidermal
growth factor receptor inhibitors for the treatment of K-Ras wild-type disease.
“Additionally, Stivarga is expected to be one of the biggest drivers of growth
in the CRC market, due primarily to its anticipated line extension as a
maintenance treatment in the first-line metastatic setting for patients with
resected liver metastases.”
The analyst adds that while multiple new
pipeline agents are expected to be launched in the CRC therapeutics market over
the forecast period, none of these drugs will have a dramatic impact on the
Sharma adds “The currently marketed brands
will continue to enjoy dominance due to their incorporation in the earlier and
more lucrative lines of treatment. “A number of new agents are likely to enter
the market, including the anti-angiogenesis inhibitors Cyramza and nintedanib.
However, these drugs will enter the competitive second- and later-line
metastatic segments of the CRC therapeutics space.”
This report provides analysis of colorectal
cancer treatment usage patterns, market characterization, the pipeline, and key
licensing and co-development deals in eight major markets, namely the US, UK,
France, Germany, Spain, Italy, Japan and Canada. The report includes annualized
historic and forecast data from 2013 through to 2020. It was built using data
and information sourced from proprietary databases, primary and secondary
research, and in-house analysis conducted by GBI Research’s team of industry
GBI Research is a market-leading provider of
business intelligence reports, offering actionable data and forecasts based on
the insights of key industry leaders to ensure you stay up-to-date with the
latest emerging trends in your markets. For more information, please contact
our Press Office on +44 (0)1204 543 537 or at email@example.com. Follow
us online for the latest industry updates: Facebook | LinkedIn | Twitter
This record has been viewed 2053 times.